

## INTERNATIONAL TRADE COMMISSION

[Investigation No. 337–TA–1348]

### Certain Cabinet X-Ray and Optical Camera Systems and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation Based on Consent Order Stipulations; Issuance of Consent Orders; Termination of the Investigation

**AGENCY:** U.S. International Trade Commission.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination (“ID”) (Order No. 4) of the presiding Chief Administrative Law Judge (“CALJ”) terminating the investigation based on consent order stipulations. The Commission has entered consent orders against respondents CompAI Healthcare (Shenzhen) Co., Ltd., CompAI Healthcare (Suzhou) Co., Ltd., Kangpai Medical Technology (Changchun) Co., Ltd., Kangpai (Beijing) Medical Equipment Co., Ltd., and Dilon Technologies, Inc. The investigation is terminated.

**FOR FURTHER INFORMATION CONTACT:** Michael Liberman, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–2392. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email [EDIS3Help@usitc.gov](mailto:EDIS3Help@usitc.gov). General information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810.

**SUPPLEMENTARY INFORMATION:** On January 3, 2023, the Commission instituted this investigation under section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, based on a complaint filed by KUB Technologies, Inc. of Stratford, Connecticut. 88 FR 113–14 (Jan. 3, 2023). The complaint alleged a violation of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain cabinet x-ray and optical camera

systems and components thereof by reason of infringement of certain claims of U.S. Patent No. 10,670,545. *Id.* at 113. The complaint also alleged the existence of a domestic industry.

The notice of investigation named as respondents the following entities: CompAI Healthcare (Shenzhen) Co., Ltd. of Shenzhen, Guangdong, China (“CompAI Shenzhen”), CompAI Healthcare (Suzhou) Co., Ltd. of Suzhou, Jiangsu, China (“CompAI Suzhou”), Kangpai Medical Technology (Changchun) Co., Ltd. of Suzhou, Jiangsu, China (“Kangpai Changchun”), Kangpai (Beijing) Medical Equipment Co., Ltd. of Suzhou, Jiangsu, China (“Kangpai Beijing”), and Dilon Technologies, Inc. of Newport News, Virginia (“Dilon”) (collectively, “Respondents”). *Id.* at 114. The Commission’s Office of Unfair Import Investigations is not a party to this investigation. *Id.*

On January 11, 2023, all of the Respondents in this investigation—CompAI Shenzhen, CompAI Suzhou, Kangpai Changchun, Kangpai Beijing, and Dilon—filed a motion to terminate this investigation based on consent orders and a memorandum in support thereof. (“Mot.”). The motion indicates that it is unopposed. *See id.* at 1.

On January 31, 2023, the CALJ issued the subject ID (Order No. 4) granting the motion. The ID found that the Respondents represent that “there are no other agreements, written or oral, express or implied between the parties concerning the subject matter of the investigation.” ID at 1 (citing Mot. at 2; 19 CFR 210.21(c)).

The ID found that, consistent with Commission Rule 210.21(c)(1)(ii), each of the Respondents provided a consent order stipulation and proposed consent order with the pending motion. *Id.* at 2–4. With respect to each of the Respondents, the ID found that their respective consent order stipulations and respective proposed consent orders conform with Commission Rules 210.21(c)(3) and 210.21(c)(4), respectively. *Id.*

Based on the motion papers and the record as a whole, the ID found that any effect the proposed consent orders may have on the statutory public interest factors does not counsel against entry of the order. *Id.* at 5. In addition, the ID found that termination of the investigation as to the Respondents by consent order will preserve Commission resources and avoid unnecessary litigation. *Id.*

The Commission has determined not to review the subject ID and to issue consent orders against respondents CompAI Healthcare (Shenzhen) Co.,

Ltd., CompAI Healthcare (Suzhou) Co., Ltd., Kangpai Medical Technology (Changchun) Co., Ltd., Kangpai (Beijing) Medical Equipment Co., Ltd., and Dilon Technologies, Inc. Accordingly, the investigation is terminated in its entirety.

The Commission vote for this determination took place on February 27, 2023.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in Part 210 of the Commission’s Rules of Practice and Procedure, 19 CFR part 210.

By order of the Commission.

Issued: February 27, 2023.

**Katherine Hiner,**  
*Supervisory Attorney.*

[FR Doc. 2023–04356 Filed 3–2–23; 8:45 am]

**BILLING CODE 7020–02–P**

## INTERNATIONAL TRADE COMMISSION

[Inv. No. 337–TA–1332]

### Certain Semiconductors and Devices and Products Containing the Same, Including Printed Circuit Boards, Automotive Parts, and Automobiles; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation in Its Entirety Based on Withdrawal of the Complaint

**AGENCY:** U.S. International Trade Commission.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the U.S. International Trade Commission has determined not to review the presiding administrative law judge’s (“ALJ”) initial determination (“ID”) (Order No. 16), granting complainant’s motion to terminate the investigation based on withdrawal of the complaint as to all respondents. The investigation is terminated in its entirety.

**FOR FURTHER INFORMATION CONTACT:** Cathy Chen, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone 202–205–2392. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email [EDIS3Help@usitc.gov](mailto:EDIS3Help@usitc.gov). General information concerning the Commission may also be obtained by accessing its

internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810.

**SUPPLEMENTARY INFORMATION:** The Commission instituted this investigation on October 14, 2022, based on a complaint filed on behalf of Daedalus Prime LLC of Bronxville, NY ("Complainant"). 87 FR 62454 (Oct. 14, 2022).<sup>1</sup> The complaint, as supplemented, alleged violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain semiconductors and devices and products containing the same, including printed circuit boards, automotive parts, and automobiles by reason of infringement of one or more of claims 1-18 of U.S. Patent No. 8,775,833 ("the '833 patent"); claims 1-18 of U.S. Patent No. 8,898,494 ("the '494 patent"); claims 1-17 of the '895 patent; claims 1-24 of U.S. Patent No. 10,049,080 ("the '080 patent"); claims 1-19 of U.S. Patent No. 10,394,300 ("the '300 patent"); and claims 1-20 of U.S. Patent No. 10,705,588 ("the '588 patent"). *Id.* at 62454-55. The complaint further alleged that an industry in the United States exists. *Id.* The notice of investigation named as respondents: Avnet, Inc. of Phoenix, AZ; Digi-Key Electronics of Thief River Falls, MN; Mercedes-Benz Group AG and Mercedes-Benz AG, both of Germany; Mercedes-Benz USA, LLC of Sandy Springs, GA; Mouser Electronics, Inc. of Mansfield, TX; Newark of Chicago, IL; NXP Semiconductors N.V. of Netherlands; and NXP USA, Inc. of Austin, TX (collectively, "Respondents"). *Id.* at 62455. The Office of Unfair Import Investigations ("OUII") is also participating in this investigation. *Id.*

Claims 6, 8, 10, 16, and 17 of the '300 patent, claims 6, 11, and 12 of the '833 patent, claims 8-12 and 16 of the '494 patent, claims 2, 4-5, 12-13, and 20 of the '588 patent, claims 9-16, 21, and 22 of the '080 patent, and all asserted claims of the '895 patent have been terminated from the investigation. *See* Order No. 11 (Dec. 13, 2022), *unreviewed by* Comm'n Notice (Jan. 11, 2023); Order No. 13 (Jan. 3, 2023),

*unreviewed by* Comm'n Notice (Jan. 30, 2023).

On January 20, 2023, Complainant filed a motion to withdraw the complaint as to all Respondents. Respondents did not oppose the motion and OUII filed a response supporting the motion.

On January 30, 2023, the ALJ issued the subject ID (Order No. 16), granting Complainant's motion to terminate the investigation in its entirety based on withdrawal of the complaint. The ID found that the motion complies with Commission Rule 210.21(a)(1), 19 CFR 210.21(a)(1), and there are no extraordinary circumstances preventing termination of the investigation. *See* ID at 2. No petition for review of the ID was filed.

The Commission has determined not to review the subject ID. The investigation is terminated in its entirety.

The Commission vote for this determination took place on February 24, 2023.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in Part 210 of the Commission's Rules of Practice and Procedure, 19 CFR part 210.

By order of the Commission.

Issued: February 27, 2023.

**Katherine M. Hiner,**

*Supervisory Attorney.*

[FR Doc. 2023-04355 Filed 3-2-23; 8:45 am]

**BILLING CODE 7020-02-P**

## DEPARTMENT OF JUSTICE

[OMB Number 1117-0014]

### Agency Information Collection Activities; Proposed eCollection, eComments Requested; Revision of a Currently Approved Collection; Application for Registration and Application for Registration Renewal; DEA Forms 224, 224A

**AGENCY:** Drug Enforcement Administration, Department of Justice.

**ACTION:** 60-Day notice.

**SUMMARY:** The Department of Justice (DOJ), Drug Enforcement Administration (DEA), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.

**DATES:** Comments are encouraged and will be accepted for 60 days until May 2, 2023.

**FOR FURTHER INFORMATION CONTACT:** If you have comments on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Scott A. Brinks, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrisette Drive, Springfield, Virginia 22152; Telephone: (571) 776-3882.

**SUPPLEMENTARY INFORMATION:** Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Evaluate whether and if so how the quality, utility, and clarity of the information proposed to be collected can be enhanced; and
- Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

### Overview of This Information Collection

1. *Type of Information Collection:* Revision of a currently approved collection.

2. *Title of the Form/Collection:* Application for Registration and Application for Registration Renewal.

3. *The agency form number, if any, and the applicable component of the Department sponsoring the collection:* DEA Forms: 224, 224A. The applicable component within the Department of Justice is the Drug Enforcement Administration, Diversion Control Division.

4. *Affected public who will be asked or required to respond, as well as a brief abstract:* Affected public (Primary): Business or other for-profit. Affected public (Other): Not-for-profit institutions; Federal, State, local, and tribal governments.

*Abstract:* The Controlled Substances Act (CSA) (21 U.S.C. 801-971) requires

<sup>1</sup> A Corrected Notice of Institution was published on November 2, 2022, 87 FR 66208 (Nov. 2, 2022). The Corrected Notice of Institution omits the determination on whether an industry "is in the process of being established" from the investigation. *Id.* at 66209.